CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its proprietary brand, Sky Premium Life, is now available for shipment across all 27 European Union Member States through Skroutz, significantly expanding the brand's international reach. A total of 96 Sky Premium Life products are now accessible to consumers across all 27 European Union Member States through Skroutz, with shipments reaching key markets across Western Europe, Northern Europe, and Central and Eastern Europe. The countries covered include Austria, Belgium, Bulgaria, Croatia, Cyprus,

6/4/26 3:57:00 PM ET

$COSM

Other Pharmaceuticals

Health Care

Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value

Company identifies real estate, digital assets, and marketable securities, among others, as potential sources of liquidity — with a combined value of approximately $20 millionProceeds could fund a meaningful acquisition or eliminate debt entirelyCompany remains fully committed to its core healthcare operations CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is exploring the monetization of non-core assets, having identified approximately $20 million in assets that can be converted to liquidity without impacting the Company's operational capabili

6/4/26 9:25:00 AM ET

$COSM

Other Pharmaceuticals

Health Care

Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent Share Price Decline

Significant Deleveraging: Total liabilities decreased by $4.5 million, or 9.6%, quarter-over-quarter, while stockholders' equity increased 7.6%Landmark Financing: R&D division in discussions with the European Investment Bank for financing of up to €25 millionCapital Structure Simplification: 4,874,126 Series B Warrants expired unexercised, eliminating ~38% of total warrant overhang with zero shareholder dilutionReal Estate Value: Wholly-owned facilities independently valued at approximately $15 million — exceeding current market capitalization Balance Sheet Transformation: Guidance projects stockholders' equity of $92.3 million by 2029, driven by a growing cash position of $62.9 million fro

6/2/26 8:00:00 AM ET

$COSM

Other Pharmaceuticals

Health Care

$COSM
Leadership Updates

Live Leadership Updates

View All

Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions

Continues to deliver record revenue and improving operating metricsSignificant expansion in the United States underway, with NOOR and other Sky Premium Life products expected to drive strong profitability supported by gross margins of approximately 75%NOOR Collagen alone is projected to generate more than $12 million in annualized revenue Strong growth expected ahead, driven by organic progress and M&A pipeline including a recent LOI to acquire an $11.5 million pharmacy distribution network Holds valuable non-core strategic real estate and digital assets with an estimated fair market value exceeding $18 million, providing meaningful balance sheet flexibilityEvaluating potential monetization

3/19/26 12:45:00 PM ET

$COSM

Other Pharmaceuticals

Health Care

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

2/24/26 12:30:00 PM ET

$COSM

Other Pharmaceuticals

Health Care

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gain

4/16/25 12:45:15 PM ET

$COSM

Other Pharmaceuticals

Health Care

$COSM
Financials

Live finance-specific insights

View All

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health. Greg S

4/30/25 12:50:09 PM ET

$COSM

Other Pharmaceuticals

Health Care

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,809 common shares, valued at $425,000, across six transactions between December 20, 2024, and January 17, 2025.As a result of these transactions, Mr. Siokas now beneficially owns 4,164,789 common shares in Cosmos Health.Greg Si

1/21/25 3:00:00 PM ET

$COSM

Other Pharmaceuticals

Health Care

Cosmos Health Issues Letter to Shareholders

CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.Dear Cosmos Health Shareholders,It has been just over a year since my previous shareholder letter, and I would like to express my sincere gratitude for your continued support. We have achieved many positive milestone

11/12/24 12:01:41 PM ET

$COSM

Other Pharmaceuticals

Health Care

SEC Form 10-K filed by Cosmos Health Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$COSM

SEC Form 10-K filed by Cosmos Health Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$COSM

$COSM
Insider Purchases

Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

$COSM
Press Releases

Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz

Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value

Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent Share Price Decline

$COSM
SEC Filings

SEC Form DEFA14A filed by Cosmos Health Inc.

SEC Form DEF 14A filed by Cosmos Health Inc.

SEC Form PRE 14A filed by Cosmos Health Inc.

$COSM
Insider Trading

Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

$COSM
Leadership Updates

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

$COSM
Financials

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

Cosmos Health Issues Letter to Shareholders

$COSM
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

SEC Form SC 13G filed by Cosmos Health Inc.

SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

SEC Form 10-K filed by Cosmos Health Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $COSM

SEC Form 10-K filed by Cosmos Health Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $COSM

$COSM Insider Purchases

Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

$COSM Press Releases

Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz

Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value

Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent Share Price Decline

$COSM SEC Filings

SEC Form DEFA14A filed by Cosmos Health Inc.

SEC Form DEF 14A filed by Cosmos Health Inc.

SEC Form PRE 14A filed by Cosmos Health Inc.

$COSM Insider Trading

Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

$COSM Leadership Updates

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

$COSM Financials

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

Cosmos Health Issues Letter to Shareholders

$COSM Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

SEC Form SC 13G filed by Cosmos Health Inc.

SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

Recent Analyst Ratings for
$COSM

Recent Analyst Ratings for
$COSM

$COSM
Insider Purchases

$COSM
Press Releases

$COSM
SEC Filings

$COSM
Insider Trading

$COSM
Leadership Updates

$COSM
Financials

$COSM
Large Ownership Changes